

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

PW MEDTECH GROUP LIMITED

普 华 和 顺 集 团 公 司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1358)

INSIDE INFORMATION

PROPOSED DELISTING OF SICHUAN RUIJIAN MEDICAL

This announcement is made by PW Medtech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09(2)(a) of the Listing Rules and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”).

PROPOSED DELISTING OF SICHUAN RUIJIAN MEDICAL

The board of directors (the “**Board**”) of the Company has recently been informed by Sichuan Ruijian Medical Technology Co., Ltd. (四川睿健醫療科技股份有限公司) (“**Sichuan Ruijian Medical**”) (a non-wholly owned subsidiary of the Company and the shares of which are quoted on the National Equities Exchange and Quotations (the “**NEEQ**”) under stock code 874652) that on October 21, 2026, the board of directors of Sichuan Ruijian Medical resolved: (i) to propose the voluntary delisting of Sichuan Ruijian Medical’s shares from the NEEQ (the “**Proposed Delisting**”); (ii) to adopt measures for the protection of the rights and interests of shareholders of Sichuan Ruijian Medical who dissent from the Proposed Delisting (the “**Dissenting Shareholder Protection Measures**”); (iii) to seek authorization from the shareholders of Sichuan Ruijian Medical for its board of directors to deal with all matters relating to the Proposed Delisting; and (iv) to convene the fifth extraordinary general meeting of Sichuan Ruijian Medical for 2026 (the “**EGM**”), expected to be held on November 6, 2026, to consider and, if thought fit, approve the foregoing matters.

Sichuan Ruijian Medical is a limited liability company established under the laws of the People’s Republic of China (the “**PRC**”) on August 6, 2013. It is a medical device company, principally engaged in the research and development, manufacturing and sales of medical device for blood purification.

As at the date of this announcement, the Company indirectly holds approximately 53.10% of the total issued shares of Sichuan Ruijian Medical, and Sichuan Ruijian Medical is a non-wholly owned subsidiary of the Company whose financial results are consolidated into those of the Group.

DISSENTING SHAREHOLDER PROTECTION MEASURES OF SICHUAN RUIJIAN MEDICAL

In order to protect the lawful rights and interests of the shareholders of Sichuan Ruijian Medical who may dissent from the Proposed Delisting, Sichuan Ruijian Medical has adopted the Dissenting Shareholder Protection Measures, the principal terms of which are summarized below:

(I) Repurchase obligor

Sichuan Ruijian Medical, its controlling shareholder, its actual controller(s), or a third party designated by its controlling shareholder or actual controller(s) (the “**Repurchase Obligor**”) will undertake to repurchase the shares of Sichuan Ruijian Medical held by the dissenting Sichuan Ruijian Medical shareholders.

(II) Eligible dissenting shareholders of Sichuan Ruijian Medical

The shares of Sichuan Ruijian Medical which are eligible for repurchase are those held by shareholders of Sichuan Ruijian Medical who (a) are registered as shareholders as of the equity registration date for the EGM; and (b) either did not attend the EGM (in person or by proxy) or attended the EGM but did not vote in favor of the resolution approving the Proposed Delisting, subject in each case to the Sichuan Ruijian Medical shareholder also: submitting a written repurchase application within the applicable validity period; not being in a position that would harm the interests of Sichuan Ruijian Medical; having no unresolved litigation, arbitration or enforcement proceedings with Sichuan Ruijian Medical relating to the repurchase; holding the relevant Sichuan Ruijian Medical shares free from any pledge, judicial freeze or other transfer restriction; and not having engaged in abnormal trading or price manipulation in respect of Sichuan Ruijian Medical's shares between the date of the relevant delisting announcement (or the date the Sichuan Ruijian Medical shareholder became aware of the Proposed Delisting, if earlier) and the suspension of trading of the Sichuan Ruijian Medical shares in connection with the Proposed Delisting.

(III) Repurchase price

The repurchase price will be the higher of (a) the cost price at which the dissenting Sichuan Ruijian Medical shareholder acquired the relevant shares of Sichuan Ruijian Medical (determined on a first-in, first-out basis, adjusted for ex-rights and ex-dividend events, and excluding transaction costs); and (b) the audited net asset value per share attributable to shareholders of Sichuan Ruijian Medical as set out in its most recent audited financial statements.

(IV) Application procedure and period

A dissenting Sichuan Ruijian Medical shareholder must submit a written repurchase application, together with supporting documentation (including proof of identity and evidence of the acquisition cost of the relevant shares), to Sichuan Ruijian Medical within one month after the delisting of its shares from the NEEQ, by personal delivery or by mail, with a scanned copy sent to Sichuan Ruijian Medical's designated email address. A Sichuan Ruijian Medical shareholder who does not submit a repurchase application in the prescribed manner within this period will be deemed to have agreed to continue holding the relevant Sichuan Ruijian Medical shares, and the Repurchase Obligor will have no further repurchase obligation to such Sichuan Ruijian Medical shareholder.

(V) Repurchase performance period

The Repurchase Obligor is required to complete the repurchase of Sichuan Ruijian Medical shares from the dissenting shareholders within 12 months from the date on which the relevant dissenting Sichuan Ruijian Medical shareholder submits a valid repurchase application.

(VI) Dispute resolution

Any dispute arising out of or in connection with the Dissenting Shareholder Protection Measures will first be resolved through amicable consultation between the parties; failing resolution, either party may bring proceedings before a people's court having jurisdiction over Sichuan Ruijian Medical's domicile.

The Board considers that the Dissenting Shareholder Protection Measures are fair and reasonable and are designed to adequately safeguard the interests of the minority shareholders of Sichuan Ruijian Medical who dissent from the Proposed Delisting. Please refer to the relevant announcement(s) made by Sichuan Ruijian Medical on the NEEQ for further details of the Proposed Delisting and the Dissenting Shareholder Protection Measures.

FINANCIAL EFFECT OF THE PROPOSED SHARE REPURCHASE(S)

As Sichuan Ruijian Medical will remain a subsidiary of the Company and continue to be consolidated into the Group's financial statements notwithstanding the Proposed Delisting, the Board does not, at this stage, expect the Proposed Delisting, if implemented, to have a material adverse impact on the Group's overall business operations or consolidated financial position. The Company will make further announcement(s) as and when appropriate in accordance with the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the SFO as further developments arise in relation to the Proposed Delisting.

LISTING RULES IMPLICATIONS

Sichuan Ruijian Medical will, after the EGM, calculate the number of its shares held by the dissenting Sichuan Ruijian Medical shareholders (if any) and the relevant repurchase price(s). Based on the entity which shall be ultimately chosen as the Repurchase Obligor and the final consideration for the repurchase of Sichuan Ruijian Medical shares (if any) from the dissenting Sichuan Ruijian Medical shareholders, should such repurchase of Sichuan Ruijian Medical shares contemplated under the Proposed Delisting process constitute a notifiable transaction or a connected transaction of the Company under Chapter 14 or Chapter 14A of the Listing Rules, respectively, the Company will, with reference to the final classification of the transaction under Chapter 14 and Chapter 14A of the Listing Rules, fulfill the applicable prescribed requirements under the Listing Rules.

The Proposed Delisting is subject to, among other things, the approval by the shareholders of Sichuan Ruijian Medical at the EGM and the completion of the relevant delisting procedures with the NEEQ, and may or may not proceed. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
PW Medtech Group Limited
Yue'e Zhang
Chairman & Chief Executive Officer

Hong Kong, October 22, 2026

As at the date of this announcement, the Board comprises one executive Director, namely, Ms. Yue'e Zhang; two non-executive Directors, namely, Mr. Jiang Liwei and Mr. Lin Junshan; and three independent non-executive Directors, namely, Mr. Wang Xiaogang, Mr. Chen Geng and Ms. Wang Fengli.